E-Mail
IMAGE: Senior author and Princess Margaret Scientist Dr. Marianne Koritzinsky s research reveals the potential of targeted therapies to exploit unique metabolic features of pancreatic cancer cells. view more
Credit: Visual Services, UHN
(Toronto, Friday, May 7, 2021) Probing the unique biology of human pancreatic cancer cells in a laboratory has yielded unexpected insights of a weakness that can be used against the cells to kill them.
Led by Princess Margaret Cancer Centre (PM) Scientist Dr. Marianne Koritzinsky, researchers showed that about half of patient-derived pancreatic cancer cell lines are highly dependent or addicted to the protein peroxiredoxin 4 (PRDX4), as a result of the altered metabolic state of the cancer cell.
The latest mixed messaging from the National Advisory Committee on Immunization highlights the urgent need for plain language in talking about COVID-19 and other public health issues
E-Mail
TORONTO - Scientists at the Krembil Brain Institute, part of University Health Network (UHN), in collaboration with colleagues at the Centre for Addiction and Mental Health (CAMH), have used precious and rare access to live human cortical tissue to identify functionally important features that make human neurons unique.
This experimental work is among the first of its kind on live human neurons and one of the largest studies of the diversity of human cortical pyramidal cells to date. The goal of this study was to understand what makes human brain cells human, and how human neuron circuitry functions as it does, says Dr. Taufik Valiante, neurosurgeon, scientist at the Krembil Brain Institute at UHN and co-senior author on the paper.
Cancer patients in chemotherapy disappointed they won t get vaccine booster sooner - BC News castanet.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from castanet.net Daily Mail and Mail on Sunday newspapers.
Provincial health minister Dr. Bonnie Henry was asked this week if B.C. would follow the lead of Ontario and Alberta in giving immune-compromised people including chemotherapy patients and organ-transplant recipients a second COVID vaccine dose within three to four weeks. “At the moment, no,” Henry said Monday. “The best protection for everybody is for more people to be immunized, to have that higher level of protection from a single dose and reduce the risk in our communities by reducing the amount of virus that’s circulating in our community.” Henry said the B.C. Centre for Disease Control is “monitoring vaccine effectiveness in every single person … so, if we start to see breakthrough infections or that the vaccine effectiveness is waning in certain populations, we can change our strategy, but we have not seen that yet.”